| Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.JAMA Dermatol | PMID 39292443PMC11411450 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Crisugabalin (HSK16149) in Adults with Postherpetic Neuralgia: A Phase 3 Randomized Clinical Trial.JAMA Dermatol | PMID 39320907PMC11581609 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.Pediatrics | PMID 39350745无 PMCID | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of a 4-Dose 20-Valent Pneumococcal Conjugate Vaccine Series in Infants: A Randomized Trial.Pediatrics | PMID 39363879无 PMCID | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Approaches and processes for paediatric chest X-ray classification used in the SHINE TB treatment-shortening trial.Int J Tuberc Lung Dis | PMID 39468018PMC7617470 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey.J Drugs Dermatol | PMID 39496135无 PMCID | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.Int J Neuropsychopharmacol | PMID 39514643PMC11561565 | 2024-Nov-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study.Diabetes Obes Metab | PMID 39157880无 PMCID | 2024-Nov | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.Ophthalmol Retina | PMID 38719191无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.J Eur Acad Dermatol Venereol | PMID 38752592无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials.Ophthalmology | PMID 38852921无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-daily fluticasone furoate/vilanterol vs once-daily fluticasone furoate in patients with asthma aged 5 to 17 years.Ann Allergy Asthma Immunol | PMID 38936466无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants.Clin Pharmacol Ther | PMID 38940465无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial.Pain Pract | PMID 38956758无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease.Clin Pharmacol Ther | PMID 38982567无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.Leuk Lymphoma | PMID 38982633无 PMCID | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Dupilumab 200 mg was efficacious in children (6-11 years) with moderate-to-severe asthma for up to 2 years: EXCURSION open-label extension study.Pediatr Pulmonol | PMID 39016623无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-10 Brain Metastases.Clin Oncol (R Coll Radiol) | PMID 39030085无 PMCID | 2024-Nov | 0.90 | This is a Phase II randomized trial of radiotherapy techniques (hippocampal sparing vs. conventional whole brain radiotherapy) for brain metastases. While it is oncology, human, randomized, and reports time-to-event endpoints (including overall survival as a secondary endpoint), it fails the required criteria because: 1) It is a Phase II trial, not Phase III/IIIb; 2) The intervention is radiotherapy alone, with no drug-containing intervention specified. The primary endpoint was neurocognitive function, not a time-to-event efficacy endpoint, though overall survival was a secondary endpoint. | 待处理 |
| Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.Osteoporos Int | PMID 39042292PMC11499533 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).J Am Acad Dermatol | PMID 39053611无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39088774无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.Ann Oncol | PMID 39098455PMC11907766 | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.J Clin Oncol | PMID 39102624PMC11527380 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil.Lancet Infect Dis | PMID 39116904无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Supplemental Nutrition Assistance Program participation gaps within a pediatric leukemia clinical trial cohort.Pediatr Blood Cancer | PMID 39129149PMC11464176 | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Item Response Theory Quantifies the Relationship Between Improvements in Serum Phosphate and Patient-Reported Outcomes in Adults With X-Linked Hypophosphatemia.Clin Pharmacol Ther | PMID 39129452无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery.J Pediatr Surg | PMID 39142955无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence.AIDS Behav | PMID 39158801PMC11530124 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39159638无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.Gastric Cancer | PMID 39162872PMC11513732 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.Breast Cancer Res Treat | PMID 39177931PMC11452482 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.Diabetes Obes Metab | PMID 39192522无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy.Radiother Oncol | PMID 39197502无 PMCID | 2024-Nov | 0.85 | The study is from a Phase III randomized trial in lung cancer, but it reports only dosimetric outcomes (dose coverage and organ-at-risk constraints) related to treatment delivery, not survival or other clinical efficacy endpoints required for KM digitization. | 待处理 |
| Three-Dimensional Conformal Radiotherapy Versus Image-Guided Intensity Modulated External Beam Radiotherapy in Locally Advanced Cervical Cancer: A Phase III Randomized Control Study.Clin Oncol (R Coll Radiol) | PMID 39209678无 PMCID | 2024-Nov | 0.75 | The study is a Phase III randomized trial in oncology (cervical cancer) with a drug intervention (concurrent cisplatin). However, the primary/primary outcomes reported are acute radiation toxicities and dosimetric parameters. The abstract states 'disease-related outcomes were assessed' but does not report any time-to-event efficacy data (e.g., OS, PFS, DFS) or Kaplan-Meier curves, hazard ratios, or survival statistics. The conclusion focuses on toxicity reduction, not survival or progression. Therefore, it lacks the required primary/key secondary time-to-event efficacy endpoint for inclusion. | 待处理 |
| Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer.Radiother Oncol | PMID 39216825无 PMCID | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.Diabetes Obes Metab | PMID 39219437无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial.Lancet Respir Med | PMID 39222649无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravenous alteplase versus tenecteplase in patients with acute posterior circulation strokes: A secondary analysis from the AcT randomized controlled trial.J Stroke Cerebrovasc Dis | PMID 39222700无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.Diabetes Obes Metab | PMID 39223856无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.Adv Ther疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39230871无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.Leukemia | PMID 39237634PMC11518977 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials.Int J Infect Dis | PMID 39241956无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.Eur J Cancer | PMID 39243730无 PMCID | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Multidisciplinary team quality improves the survival outcomes of locally advanced rectal cancer patients: A post hoc analysis of the STELLAR trial.Radiother Oncol | PMID 39243864无 PMCID | 2024-Nov | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.Lancet Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39250926无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Safety and efficacy of a novel 0.5% epinastine topical eyelid cream in allergic conjunctivitis: a phase 3 trial.Jpn J Ophthalmol | PMID 39259242PMC11607043 | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39259927无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials.J Dermatol | PMID 39269202无 PMCID | 2024-Nov | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Ann Oncol | PMID 39284381PMC11934258 | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39284383无 PMCID | 2024-Nov | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |